A phase 3 trial evaluating an investigational antiviral antibody cocktail, REGN-COV2, for the prevention of COVID-19 has been initiated by Regeneron Pharmaceuticals.

---

SOURCE: Empr.com

Click here to READ THE FULL STORY.